New horizons in osteoarthritis

Leonardo Punzi, Francesca Oliviero, Roberta Ramonda
Rheumatology Unit, Department of Clinical and Experimental Rheumatology, University of Padova, Italy

No conflict of interest in relation to this article.

Summary

Osteoarthritis (OA), also known as degenerative joint disease, is the most frequent chronic musculoskeletal disease and the leading cause of disability in elderly persons. There are currently at least 27 million persons afflicted with OA in the United States, and the annual cost to society in medical care and wage loss is expected to reach nearly $100 billion dollars by 2020, with consequent increased spending on its diagnosis and treatment, side-effect prevention, and loss of productivity. Despite this enormous burden, many aspects of OA are still unknown, with implications not only in terms of diagnosis and assessment but also with regard to therapy. Awareness of this state of affairs has attracted many researchers to this field, making OA one of the most actively studied sectors of rheumatology. Although some clinicians are unaware of recent advances, there is a large body of publications indicating that much has been achieved. Major progress has been made in formulating better definitions of risk factors, in particular in indicating the responsibility of biomechanical and genetic factors, and, with regard to pathogenesis, underlining the role of subchondral bone, cytokines and proteinases. Assessment of OA activity and its progression has been improved with the advent of biomarkers and new imaging procedures, in particular sonography and magnetic resonance imaging (MRI), but also of better clinical instruments, including more reliable patient questionnaires. Information from ongoing studies may improve the to some extent incomplete definition of OA phenotypes. Finally, promising new horizons have been opened up even with regard to the treatment of OA, which is still for the most part unsatisfactory except for surgical replacement therapy. Numerous new substances have been formulated and the findings of trials studying their effects are encouraging, although much has yet to be done.

Key words: osteoarthritis; cartilage; biomechanics; cytokines; proteinases; biomarkers; IL-1; therapy

Introduction

Osteoarthritis (OA) is the most frequent chronic musculoskeletal disease and is undoubtedly by far the most common cause limiting the daily activities of the elderly population [1]. There are currently at least 27 million persons afflicted with OA in the United States, costing the economy approximately $60 billion annually [2, 3]. The annual cost to society in medical care and wage loss due to arthritis is expected to reach nearly $100 billion dollars by 2020, with consequent increased spending on diagnosis and therapy, side-effect prevention and lost earnings. At present, approximately 40% of adults aged over 70 suffer from OA of the knee, of these 80% suffer from limitation in movement and 25% are impaired in carrying out their daily activities [4]. It is also important to underline the synergistic effects of other conditions coexisting with OA, in particular obesity and cardiovascular diseases [5, 6].

Despite this enormous burden, OA has not received adequate attention from civil authorities and clinicians, including rheumatologists themselves. An increasing number of researchers have, nevertheless, been attracted to this in some respects “unpopular” field. The reason for this incongruence may at least in part be explained by the presence in the past of a series of misconceptions such as an epidemiologic approach for the most part focussing on the patient’s radiographic profile rather than on clinical characteristics and phenotypes, excessive attendance to traditional radiographic signs, which in this case often become evident only late in the disease’s progression, inadequate exchanges between basic researchers and clinicians on scientific findings and patients’ needs, and limited therapeutic alternatives that have frequently proved disappointing. Awareness of these inconsistencies may perhaps facilitate the search for untried paths aiming to uncover new data clarifying unresolved questions such as the role of risk factors, fostering early diagnosis even in the pre-radiological phase, identifying reliable disease activity indices and, finally, verifying new therapies. Some of these objectives are close to attainment, as demonstrated by numerous findings published in the literature and outlined in this review.
Risk factors

OA, classified as primary or idiopathic, usually develops without known cause. An increasing body of evidence suggests that some risk factors such as genetic predisposition, age, obesity, female sex, greater bone density, joint laxity, and excessive mechanical loading may play a part in its development. Although age is the most important risk factor in OA it is still unclear whether it should be considered an ageing process or a “true” disease, since the former occurs in all members of the population while the latter affects only a limited subset [7, 8]. In addition, despite the fact that almost all elderly people show radiographic findings of OA, the number of subjects who actually complain of symptoms directly related to the disease is much lower [9, 10]. Heberden’s nodes are, for example, a case in point, as few patients complain about their bony hand outgrowths despite the frequency with which radiographic alterations of these bone swellings are noted in the general population. Some investigators have recently voiced conjecture regarding the role of genetic factors in determining longevity and the predisposition to age-associated diseases including OA [11], while others speculate that some environmental factors, in particular mechanical factors, may accelerate and accentuate these processes [12].

Genetic predisposition

Genetic predisposition may have an effect on OA in a variety of ways, by e.g. influencing susceptibility to the disease, age at onset, progression, subtype and, probably, response to treatment. Identifying susceptibility genes may be useful in helping to explain the disease’s mechanisms, since it may uncover the primary biological events causing OA [13].

The familial aggregation of clinical and radiographic features of OA was first demonstrated in the 1940s by the classical studies carried out on Heberden’s nodes, and has since been confirmed, with regard to hand and knee OA, by several community-based studies [14–17]. A recent analysis of x-ray features of hand and knee OA in twins recruited from a healthy population demonstrated that genetic factors accounted for between 39% and 65% of the variation in liability to disease at these two sites [18].

With regard to the most important susceptibility genes recently identified, frizzle related protein 3 (FRZB) [19] and asporin (ASPN) [20] are particularly interesting. Studies carried out in the UK have reported that two single nucleotide polymorphisms (SNP) of FRZB increase the risk of knee and hip OA in Caucasian women but not in men [21, 22]. SNP’s role was not confirmed in a Spanish population, in which another SNP tended to be more frequent in patients with clinical disease in multiple joints, and specifically in women with hip OA [23, 24]. With regard to ASPN, its association with knee or hip OA has been observed in the Japanese [20], but not in European populations [25–28].

Many of the gene defects affecting the formation of the cartilage matrix and patterning of skeletal elements during development result in a variety of congenital cartilage dysplasias with Mendelian inheritance, though occurring only very rarely [29]. Interestingly, OA is most often site-specific in individuals with skeletal dysplasias. Mutations in the type II collagen gene (COL2A1), for example, cause spondylo-epiphyseal dysplasia congenita. Although this cartilage-specific collagen is the most abundant component of articular cartilage in all joints, the OA phenotype of the disease is site-specific [30]. Hip OA is very severe, spine and knee OA is moderately severe, but the hand is normal. Mutations in COMP (cartilage oligomeric matrix protein), another abundant component of articular/epiphyseal cartilage, cause early, severe OA but the spine and peripheral joints are unaffected [31]. The adverse effects of joint malalignment and congruity in these patients may contribute to the possible loss of articular cartilage and in some cases early OA onset [29–31].

Genetic predisposition may also influence the type of reactivity of some innate functions involved in the inflammatory response. Botha-Scheepers et al. have demonstrated that joint space narrowing (JSN) was present 24 months after baseline in 33.7% of symptomatic patients with knee OA [32]. After stimulation of whole blood samples with lipopolysaccharide (LPS) it was found that patients in the highest quartile of tumour necrosis factor (TNF)α production had a 2½-fold increased risk while patients in the highest quartile of interleukin (IL)-10 production had a sixfold increased risk. Other studies produced similar results. In the Genetics of Osteoarthritis and Progression (GARP) study, the role of the C-reactive protein (CRP) gene in hand OA (HOA) was evaluated by determining serum levels of CRP using a high sensitivity (hs) method and assessing genetic variations of the CRP gene by genotyping five tagging SNPs [33]. A haplotype of the CRP gene, linked to a high basal hsCRP level, was associated with severe HOA, indicating that innate high basal serum-hsCRP levels may influence OA onset and severity [33].

Another interesting study by Stern et al. supports the hypothesis of a genetic association between erosive hand OA (EHOA), a severe subtype of hand OA, and an SNP on gene encoding IL-1β [35].

Biomechanical reactivity

Biomechanics is the term commonly used in OA to define the biochemical reaction to mechanical stimuli, a process considered crucial for the disease’s modern pathogenesis. Joint structures are organised for functions essentially related to joint motion, including load transfer across the joint. Thus, while “normal” loading is useful and necessary to stimulate physiological changes of joint structures, “abnormal” loading, especially during activity, may accelerate the disease’s onset and progression [36, 37]. The biological effects induced by mechanical factors may destabilise the normal coupling of degradation and synthesis of articular
cartilage chondrocytes, extracellular matrix and subchondral bone. Several studies have demonstrated that some mechanical joint derangements due to meniscectomy or anterior cruciate ligament injuries may dramatically increase the incidence and progression of knee OA [36, 37]. However, just as with age, these events occur only in some subjects who are probably predisposed. Clarifying the relationship between mechanical injuries and the development of articular cartilage abnormalities can be considered one of the major challenges facing modern rheumatological research.

Chondrocytes are programmed to respond to direct biomechanical perturbation and act as “mechanosensors” by means of specific sensitive receptors, many of which bind to extracellular matrix (ECM) components [38, 39] (fig. 1). The best studied are the integrins, which act as receptors for fibronectin (FN), and type II collagen fragments [38–40]. Activation of these receptors can stimulate the production of inflammatory cytokines, chemokines, and matrix-degrading proteinases, mainly metalloproteinases (MMPs) [40]. In a physiological setting integrins modulate cell/ECM signalling, which is essential in regulating growth and differentiation as well as in maintaining cartilage homeostasis. Abnormal integrin expression during disease activity may alter cell/ECM signalling and modify chondrocyte synthesis activity with subsequent imbalance of destructive or catabolic cytokines over regulatory factors and/or anti-inflammatory or anabolic cytokines [41]. “Abnormal” mechanical loading stimulates depletion of proteoglycans, damages the collagen network and reduces the synthesis of cartilage matrix proteins [42]. In response to traumatic injury global gene expression is activated, resulting in increased expression of inflammatory mediators, including that of cytokines and proteases [38–42].

**Cytokines, growth factors and metalloproteinases**

Cytokines, involved in cell-cell interactions, are hormone-like proteins that regulate the intensity and duration of the immune response [43]. Cytokines and growth factors involved in OA may be released from different cellular sources, such as chondrocytes, synovial cells or osteocytes. It is almost certain that cytokines are involved in OA development and progression, and that blocking cytokines is useful in protecting cartilage from damage [44–46].

IL-1 and TNF are the most important and best studied cytokines in OA. IL-1, released either by the synovium [47] or the chondrocytes [48], could stimulate the latter to produce most or all of the proteinases involved in cartilage destruction [49, 50]. TNFα and IL-1 may also inhibit the synthesis of proteoglycans and type II collagen [51, 52]. Chondrocytes in OA cartilage express IL-1, IL-1β converting enzyme (casepase-1) and type 1 IL-1 receptor (IL-1RI) [38]. In turn, IL-1 synthesised by chondrocytes may be able to induce the expression of MMPs and aggrecanases [51, 52], the synthesis of prostaglandin E2 (PGE2) [53, 54] and the production of nitric oxide (NO) via inducible NO synthetase (NOS, or NOS2) [48, 55, 56]. IL-1β also induces other proinflammatory cytokines such as IL-6, leukaemia inhibitory factor (LIF), IL-17, and IL-18 and chemokines, including IL-8 [38, 57]. IL-6 plays an important role in influencing cartilage metabolism. Guerne et al. analysed the effects of IL-6 on proteoglycan synthesis by human articular chondrocytes in the presence of sIL-6R [58], they found that sIL-6R potentiates the inhibitory effect of IL-6 on proteoglycan synthesis by articular chondrocytes, but the overall effect of IL-6 + IL-6sR is moderate compared to that of IL-1 [58].

Cytokines involved in cartilage metabolism can be grouped into 3 categories: catabolic cytokines, which include IL-1β, TNFα, IL-17, and IL-18; inhibitory cytokines, which include IL-4, IL-10, IL-11, IL-13; IL-1 receptor antagonist, and interferon-γ; and anabolic cytokines, which comprise insulin-like growth factor 1, TGFβ1, TGFβ2, TGFβ3, fibroblast growth factor (FGF)-2, FGF-4, FGF-8, BMP-2, BMP-4, BMP-6, BMP-7, BMP-9, and BMP-13 [46].

Cytokines synergise with one another in normal joint tissues in maintaining a perfectly balanced network [59]. An imbalance in this system could have important implications for the pathogenesis of most arthropathies, including OA [60, 61]. In this context the role of subchondral bone region, in combination with or independently of the synovial membrane, which represents the most abundant source of cytokines in OA, seems increasingly relevant [62, 63].

As underlined above, the most relevant destructive effects of cytokines on the cartilage are mediated by MMPs, including ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) [64–68]. Among the members of the MMP family relevant roles are played by MMP-13, involved in the degradation of collagen type II in OA cartilage [67], and by ADAMTS4 and ADAMTS5, believed to be key proteases in the degradation of aggrecans [69, 70].

**Adipokines**

The term “adipokine” is generally applied to biologically active substances found in the adipocytes of white adipose tissue (WAT), although they may be synthesised at other sites too [71]. Adipokines include a variety of pro-inflammatory peptides or cytokines which contribute to the “low-grade inflammatory state” of obese subjects [72, 73]. The best known of this family are leptin, adiponectin and resistin. Leptin is a 16 kDa non-glycosylated peptide hormone belonging to the class I cytokine superfamily chiefly produced by adipocytes [74]. Leptin can be considered a cytokine-like hormone with pleiotropic actions exerting biological influences by binding to its receptors [75]. Leptin is able to modulate cells involved in immune/inflammatory reactions, including monocytes/macrophages, neutrophils, dendritic cells and T-cells [76]. Leptin production is much higher in OA human cartilage than in normal cartilage [77]. The finding that administration of exogenous leptin increases IGF1 and TGFβ1 production by rat knee-joint cartilage has suggested that high circulating leptin levels in obese individuals may protect cartilage from degeneration [77]. Under pathological conditions, however, control of matrix homeostasis by chondrocytes in the joint is lost. In cultured human and murine chondrocytes, NO synthetase activation by IL-1 is increased by leptin via a mechanism involving JAK2, PI3K, MEK1 and p38 [78]. It has recently been demonstrated that leptin is also involved to induce synthesis of relevant MMPs involved in cartilage damage, such as MMP9 and MMP13 [79].
Adiponectin is produced largely by WAT and has structural homology with collagens VIII and X and complement factor C1q [80]. Adiponectin acts via two receptors, one (AdipoR1) found predominantly in skeletal muscle and the other (AdipoR2) in the liver [81]. Adiponectin has a wide range of effects in immune and inflammatory diseases and exerts relevant actions on innate and adaptive immunity [71]. In contrast to a ‘protective’ role against obesity and vascular diseases, it seems that in skeletal joints adiponectin may be proinflammatory and involved in matrix degradation [79]. Chondrocytes present functional adiponectin receptors, activation of which leads to the induction of NOS2 via a signalling pathway involving PI3 kinase; and adiponectin-treated chondrocytes similarly increase IL-6, TNF and MCP1 (monocyte chemotactic protein 1) synthesis [82].

Resistin is a dimeric protein that received its name from its apparent induction of insulin resistance in mice, thus providing a possible link between obesity and insulin resistance [83]. Levels of both resistin and leptin are elevated in obese individuals. Resistin is produced by WAT and monocyte/macrophages, but also by cartilage itself, and is a very powerful proinflammatory cytokine, increasing production of IL-1, TNF-α, and various chemokines [84]. Following traumatic joint injury, resistin levels are increased, causing matrix degradation and release of inflammatory cytokines from articular cartilage [85].

Serum levels of adiponectin and resistin were recently measured in 48 women with erosive HOA (EHOA), 27 with non-EHOA and 20 without HOA as controls [86]. Adiponectin but not resistin were significantly higher in EHOA than in non-EHOA or healthy controls. Both adiponectin and resistin neither correlated with the levels of CRP nor were related to body mass index, thus suggesting that adiponectin may play a role in the pathophysiology of the erosive subset of HOA [86].

Subchondral bone

An increasing body of evidence shows that subchondral bone is actively involved in the pathogenesis of OA through several possible mechanisms, including a defect in its role as a shock absorber; abnormal osteocyte function; increased production of bone-derived products, cytokines, and MMPs [38, 62, 63]. It is still unclear whether changes occurring in subchondral bone precede or follow OA onset. In any case, it is possible that a crucial role is played by the vascular invasion of bone marrow tissue into this region [87]. In agreement with this, it has been seen that concentrations of some inflammatory cytokines such as IL-1, TNF and IL-6 are significantly up-regulated, supporting the hypothesis that vascularised subchondral plates may increase the synthesis of cytokines and proteolytic enzymes, thereby contributing to the degradation of adjacent hyaline cartilage [88].

The importance of angiogenesis in OA has recently been discussed in detail [89]. Angiogenesis and inflammation are closely integrated processes in OA and may affect disease progression and pain. Angiogenesis may promote chondrocyte hypertrophy and endochondral ossification, contributing to radiographic changes in the joint. In association with inflammation it may sensitize nerves and thus increase pain. Innervation may also accompany vascularization of the articular cartilage, where compressive forces and hypoxia may stimulate these new nerves.

Several experiments have demonstrated that inadequate fluid flow round osteocytes may result in osteocyte apoptosis, attraction of osteoclasts and excavation of the non-viable bone [90, 91]. In some cases partial or total collapse of subchondral bone may take place, as can be seen in avascular necrosis (AVN) [87, 92]. Subchondral bone ischaemia may be crucial to OA development in several ways, first of all by blocking the nutrient and oxygen supply, usually furnished by the dense subchondral vasculature in close proximity to the cartilage, and via microchannels that penetrate the subchondral mineralisation zone, permitting communication between bone and cartilage [87].

These events at the subchondral bone level are clearly demonstrated by high resolution magnetic resonance imaging (MRI) of the joints. Bright areas of subchondral bone on MRI, commonly observed in both early and established OA and in individuals with painful joints [93], probably correspond to areas of bone marrow-like oedema lesions (BMLOL), occurring idio-pathically or in response to bone trauma [93]. Longitudinal studies have shown that BMLOL are an important risk factor for structural deterioration in knee OA [94–96]. It has recently been shown that subchondral cysts, characteristic of established and severe OA, develop in preexisting regions of subchondral BMLOL [97]. While BMLOL’s origin is unknown, it may be secondary to ischaemic episodes perhaps exacerbated by reperfusion injuries [98, 99].

Biomarkers

Molecular markers in OA have been the object of growing attention due to their potential usefulness in formulating early diagnosis, in assessing disease activity and severity and in evaluating drug effects [100]. In this respect, biochemical markers or biomarkers are ideal, as they are non-invasive and inexpensive measures [101]. The NIH-funded Biomarkers Network, a multidisciplinary group interested in the development and validation of biomarkers, has recently proposed the “Burden of Disease, Investigative, Prognostic, Efficacy of Intervention and Diagnostic” (BIPED) biomarker classification [102]. It may be concluded, however, that although a great number of substances are continually proposed, only a few can be considered true OA “disease markers” [100–108].

Until now no biomarkers appear to have been able to assist in OA disease diagnosis in the pre-radiological stages, but with the recent introduction of highly sensitive (hs) immunoassays, a growing number of studies have suggested that CRP may be a marker of OA activity and severity [106]. It would seem that higher CRP levels may predict worse disease outcomes over the next 4 years [109].

It has been observed that serum hsCRP levels are higher in patients with EHOA than in non-EHOA patients [110]. This probably reflects disease activity rather than subtype, since hsCRP levels correlate with clinical activity scores [110]. As MMPs are particularly involved in cartilage degradation, their levels or activities have been investigated in an attempt to obtain information
concerning OA severity or progression [111]. The most abundant MMP both in serum and SF is MMP-3 [111, 112]. It has been hypothesised that pro-matrix MMP-3 acts as a marker for post-traumatic cartilage degradation [113, 114].

The molecular markers most useful in identifying cartilage synthesis or degradation originate from different articular sources such as cartilage, bone and synovial tissue [101, 102]. Serum hyaluronan (HA), a marker of synovial proliferation and hyperactivity, appears to reflect OA progression [115, 116]. Other interesting biochemical markers are serum keratin sulphate (KS), COMP, YKL-40, and urinary C-terminal crosslinking telopeptides of collagen types I and II (uCTX-II) [106]. COMP concentrations in synovial lavage fluids as well as in serum are an early indicator of radiographic progression at follow-up [117–119]. It has also been seen that COMP is the most sensitive test for identifying subjects affected with the genetic form of premature OA [120, 121]. In the ECHODIAH study, performed by French investigators to determine whether systemic markers of bone, cartilage, and synovium can predict structural progression of hip OA, 10 markers were evaluated: N-propeptides of collagen types I and III, COMP, YKL-40, HA, MMP-1 and MMP-3, CRP and urinary C-terminal crosslinking telopeptides of collagen types I and II (uCTX-II) [122]. Combined measurements of uCTX-II and sHA were found to be the best predictor of structural progression in hip OA [122]. Coll 2-1 and Coll 2-1 NO2, new serum biochemical markers, have recently been used to study oxidative related type II collagen network degradation in patients with OA and RA [123]. No relationship was found between radiological OA severity and serum levels of these markers, but, interestingly, Coll 2-1NO2 was correlated with CRP in the sera of OA and RA patients [123]. Coll 2-1, Coll 2-1NO2 and myeloperoxidase (MPO) were all higher in the serum of patients with EHOA than in that of non-EHOA subjects, although only the rise in MPO was significant [124]. In another study, Coll 2-3/4C epitope levels were higher in the EHOA patients than in the nodal non-EHOA subjects and controls [125].

Phenotyping OA

In their daily practice clinicians are no doubt frustrated by the bulk of basic research activities concerning OA compared with the few products really available for their patients. The task of clearly defining markers that can be used for early pre-radiological diagnoses and assessment of disease activity or progression is, on the other hand, quite arduous in the absence of a well established clinical definition. It must be said that much effort continues to be expended in improving the quality of clinical observation.

In this context an important step was taken by the American College of Rheumatology in establishing criteria for diagnosis and classification of OA with emphasis on the role of pain [126]. Since that time constant advances have been made in the assessment of symptoms and signs, facilitating early diagnoses and, at times, identification of a subtype or variant not yet detectable by means of radiographic or laboratory findings. EHOA, for example, can be identified by assessment of clinical features even before x-ray identification is possible. In fact, this subtype of hand OA is characterised clinically by frequent inflammatory episodes at times persisting for years and, at times, involving several joints simultaneously [127]. By contrast, flares of nodal HOA occur chiefly at the onset of each joint’s involvement, in a “stuttering” onset polyarthritis of distal interphalangeal (DIP)s and proximal interphalangeal (PIP)s resembling a “monoarthritis multiplex” [127]. Typically, the patient develops discomfort followed by swelling of a single inter-phalangeal joint, later involving another I-P joint and then another, producing the “stuttering onset” of polyarthritis of distal and proximal I-P joints. Instability and ankylosis of IP joints are, moreover, almost always a feature only of EHOA [128]. Since EHOA is commonly detected by MRI [129], in future the criteria defining EHOA will probably also include specific clinical features in addition to erosion [130].

In keeping with the idea that the modern approach to OA should include adequate evaluation of affected patients, advancement in disease assessment has been obtained by the use of reliable questionnaires, in particular those evaluating quality of life, function pain and radiographic progression [131–133]. Under the auspices of the OARSI (Osteoarthritis Research Society International) and the OMERACT (Outcome Measures in Rheumatology Clinical Trials) initiative, an international working group was recently set up to define the theoretical requirements for total joint replacement in knee and hip OA for use by clinical trials evaluating potential disease-modifying drugs [134]. It was their decision that the domains of pain, physical function and joint structure on x-rays would be combined as a surrogate measure of outcome [135, 136].

High scores on self-reported health-related quality of life (HRQOL) questionnaires have been found to be associated with higher odds of visiting a physician, using analgesics or non-steroidal anti-inflammatory drugs (NSAIDs), and having had arthroplasty [137]. The relationship between mental health and physical disability is a complex problem particular to OA. It has been demonstrated that the depression commonly found in older persons is associated with functional disability [138], and that depression and pain are more important predictors of disability than radiographic evidence of degenerative joint alterations in patients with hip or knee OA [139]. It has also been observed that treatment for depression, e.g. antidepressants and/or psychotherapy, may reduce pain and improve functional status and quality of life in older patients with OA [140].

It is to be hoped that the availability of these new tools will help to differentiate OA subtypes and improve health professionals’ attitude to their patients.

Future therapeutic strategies

One of the most frequent complaints by clinicians treating OA patients is their frustration with the ineffectiveness of the therapeutic tools that are available. As underlined by recent recommendations, one of the reasons for this state of affairs is probably the lack of a global OA management strategy [141–145]. There is no doubt that, with respect to other rheumatic diseases, pharmacological treatment of OA is the least satisfactory. Advances in surgical treatment are much more evident, with regard not only to joint replacement but also to tissue engineering, so-called “biosurgery” [146–147]. These have been linked to space-filling materials, also known as scaffolds, capable of regenerating or repairing cartilage [148]. Cell transplantation has not yet been attempted in the treatment of OA.
Just as in other types of arthritis, and bearing in mind the importance of genetic predisposition, even gene therapy could be a powerful tool for the future. However, it is unlikely that in future strategies modification of relevant gene mutations can be used to treat OA. A more realistic approach may be to try modifying the synovium or subchondral bone to enhance synthesis of the cartilaginous matrix, inhibit its breakdown, or a combination of the two [149–151]. Unfortunately, all the results currently available concern either animal models or in vitro studies, since no human clinical gene therapy trials have been implemented.

A number of ongoing trials are exploring the use of anticytokine therapy. Three strategies currently targeting the activities of catabolic cytokines include: inhibiting the proteinases that degrade cartilage matrix proteins [152], suppressing cytokine-induced signalling pathways [153, 154] and inhibiting chondrocyte apoptosis using inducible NO synthase or caspase inhibitors [155]. As several proteinases involved in OA share overlapping substrate specificities and structural epitopes, some proteinase inhibitors appear to be effective in both animal models and human clinical trials [156]. Krezski et al. have, however, recently reported that PG-116800, the MMP inhibitor, is not only ineffective in modifying the matrix structure in OA patients but seems to provoke numerous musculoskeletal adverse effects [157]. Strategies to suppress cytokine-induced signalling pathways include: cytokine neutralisation, receptor blockade, inhibition of cytokine processing, inhibition of cytokine synthesis or action, and combined therapies [44, 158].

In ongoing trials drug administration is primarily through oral and infusion therapy and is only rarely intraarticular. It is possible that some factors may limit the efficacy of anti-cytokine drugs administered by this latter pathway, including a shorter half-life. This is probably the reason why anakinra, the IL-1 receptor antagonist, was found to be effective in modifying disease progression in animal models [159, 160] and in a 12-week open-label study on symptomatic human knee OA [161], but caused no statistical improvement over placebo after one month in a follow-up controlled trial [162]. In a prospective randomised controlled trial autologous interleukin-1 receptor antagonists were however found to improve function and symptoms in OA patients compared to placebo [163].

The intraarticular pathway has in any case proven to be a satisfactory tool for patients and physicians alike, as demonstrated by the fact that, together with hyaluronate derivatives, it has won worldwide popularity [164–168]. Many pharmaceutical companies are in fact anxious to accelerate research in this area, as demonstrated by the many interesting products now being tested in animals and in phase I human trials.

References

1. Verbrugge LM, Patrick DL. Seven chronic conditions: their impact on US adults’ activity levels and use of medical services. Am J Public. 1995;85:173–82.
2. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;60:26–35.
3. Elders MJ. The increasing impact of arthritis on Public Health. J Rheumatol. 2000;27:6–8.
4. World Health Organisation and the Bone and Joint Decade. Available at http://www.boneandjointdecade.org.
5. Corti MC, Guralnik JM, Sartori L, Baggio G, Manzato E, Pezzotti P, et al. The impact of cardiovascular and osteoarticular diseases on disability in older men and women: rationale, design and sample characteristics of the PRO.V.A (Progetto veneto Anziani) Study. J Am Geriatr Soc. 2002;50:1535–40.
6. Calza S, Decarli A, Ferrarini M. Obesity and prevalence of chronic diseases in the 1999–2000 Italian National Health Survey. BMC Public Health. 2008;8:140–9.
7. Forbes WF. General concepts of the association of ageing and disease. In “Osteoarthritis. Public Health implications for an ageing population”. Hamer man D, Ed. Johns Hopkins University Press, Baltimore and London, 1997, pp 3–14.
8. Crepaldi G, Punzi L. Aging and osteoarthritis. Aging Clin Exp Res. 2003;15:355–8.
9. Bagge E, Bjelle A, Edén S, Svantorg A. Clinical and radiological find ings in 79 and 85 year olds. Ann Rheum Dis. 1991;50:535–9.
10. Corti MC, Rigon C. Epidemiology of osteoarthritis: prevalence, risk factors and functional impact. Aging Clin Exp Res. 2003;15:359–63.
11. Hamerman D. Ageing and the musculoskeletal system. Ann Rheum Dis. 1997;56:578–85.
12. Kirkwood TBL. What is the relationship between osteoarthritis and ageing? Baillière’s Clin Rheumatol. 1997;11:683–93.
13. Ikegawa S. New gene associations in osteoarthritis: what do they provide, and where are we going? Curr Opin Rheumatol. 2007;19:429–34.
14. Stecher RM, Heberden’s nodes: heredity in hypertrophic arthritis of the finger joints. Am J Med Sci. 1941;210:801–9.
15. Kellgren JH, Lawrence JS, Bier F. Genetic factors in generalised osteoarthritis. Ann Rheum Dis. 1963;22:237–55.
16. Felson DT, Coupropitrees NN, Chaisson CE, Hannan MT, Zhang Y, McAlindon TE, et al. Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: the Framingham study. Arthritis Rheum. 1998;41:1064–71.
17. Hirsch R, Lethbridge-Cejku M, Hanssen B, Scott WW Jr, Reischle R, Pluto CC, et al. Familial aggregation of osteoarthritis: data from the Baltimore Longitudinal Study on Aging. Arthritis Rheum. 1998;41:1227–32.
18. Spector TD, Cicuttini F, Baker J, Loughlin J, Hart D. Genetic influences on osteoarthritis in women: a twin study. BMJ. 1996;312:940–3.
19. Loughlin J, Dowling B, Chapman K, Marmorel L, Mustafa Z, Southam L, et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci. USA 2004;101:9757–62.
20. Kizawa H, Iida A, Sudo A, Miyamoto Y, Fukuda A, et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet. 2005;37:138–44.
New horizons in osteoarthritis

Valdés AM, Loughlin J, Oene MV, Chapman K, Surdulescu GL, Doherty M, et al. Sex and ethnic differences in the association of ASPN, CALM1, COL2A1, COMP, and FRZB with genetic susceptibility to osteoarthritis of the knee. Arthritis Rheum. 2007;56:137–46.

Lane NE, Lian K, Nevitt MC, Zmuda JM, Lui L, Li J, et al. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum. 2006;54:1246–54.

Rodriguez-Lopez J, Pombo-Suarez M, Liz M, Gomez-Reino JJ, Gonzalez A. Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis. Ann Rheum Dis. 2007;66:1052–5.

Snelling S, Ferreira A, Loughlin J. Allelic expression analysis suggests that cisacting polymorphism of FRZB expression does not contribute to osteoarthritis susceptibility. Osteoarthritis Cartilage. 2007;15:90–2.

Mustafi Z, Dowling B, Chapman K, Sinnesheimer JS, Carr A, Loughlin J. Investigating the aspartic acid (D) repeat of asporin as a risk factor for osteoarthritis in a UK Caucasian population. Arthritis Rheum. 2005;52:3502–6.

Kaliakatsos M, Tzetta M, Kanavakis E, Fytili P, Choulis A, Karachalias T, et al. Asporin and knee osteoarthritis in patients of Greek origin. Osteoarthritis Cartilage. 2006;14:609–11.

Rodriguez-Lopez J, Pombo-Suarez M, Liz M, Gomez-Reino JJ, Gonzalez A. Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians. Arthritis Res Ther. 2006;8:R55.

Valdés AM, Loughlin J, Oene MV, Chapman K, Surdulescu GL, Doherty M, et al. Sex and ethnic differences in the association of ASPN, CALM1, COL2A1, COMP, and FRZB with genetic susceptibility to osteoarthritis of the knee. Arthritis Rheum. 2007;56:137–46.

Li Y, Xu L, Olsen BR. Lessons from genetic forms of osteoarthritis for the pathogenesis of the disease. Osteoarthritis Cartilage. 2007;15:1101–5.
New horizons in osteoarthritis

Bertazzolo N, Punzi L, Stefani MP, Cesaro G, Pianon M, Finco B, Todesco S. Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions. 1994;41:90–2.

Punzi L, Calò L, Pilebani M. Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci. 2002;39:63–88.

Hulejova H, Baresova V, Kleží Z, Polanská M, Adam M, Senolt L. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine. 2007;38:151–6.

Martel-Pelletier J, La jeunesse D, Pelletier J-P. Subchondral bone and osteoarthritis progression: a very significant role. In “Osteoarthritis, Inflammation and Degradation: A Continuum”. J. Buckwalter, M. Lotz and J-F Lotz Eds. IOS Press 2007, pp 206–18.

Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001;44:585–94.

Arner EC. Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol. 2002;2:322–9.

Rengel Y, Ospeil C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther. 2007;9:221.

Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol. 2008;4:128–35.

Plass A, Osborn B, Yoshihara Y, Bai Y, Bloom T, Nelson F, Mikecz K, Sardy JD. Aggrecanase-mediated cartilage degradation. Cell Mol Immunol. 2007;4:1–13.

Tilg H, Morgen AH. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Rev Immunol. 2006;6:772–83.

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2006;115:911–9.

Dayer JM, Chicheportiche R, Juge-Aubry C, Meier C, Matarese G, Moschos S, Mantzoros CS. Leptin in immunology, J Immunol. 2005;174:3137–42.

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2006;115:911–9.

Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007;4:1–13.

Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006;393:7–20.

Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005;434:648–52.

Thonar EJ, Manicourt DH. Noninvasive markers in osteoarthritis. In: Moskowitz RW, Howell DS, Altman RD, Buckwalter JA, Goldberg VM. New horizons in osteoarthritis. Saunders Philadelphia, 3rd edition 2001;293–313.

Swiss Medical Weekly  www.smw.ch – Early Online Publication, 28. April 2010 8
New horizons in osteoarthritis

105 Punzi L, Oliviero F, Ramonda R, Valvason C, Sfriso P, Todesco S. Laboratory investigations in osteoarthritis. Aging Clin Exp Res. 2003;15:373–9.

106 Punzi L, Oliviero F, Ramonda R, Valvason C, Todesco S. Laboratory findings in osteoarthritis. Semin Arthritis Rheum. 2005;34:2S:58–61.

107 Punzi L, Oliviero F, Ramonda R. Biomarkers of matrix fragments, inflammation markers in osteoarthritis. In Osteoarthritis, Inflammation and Degradation: A continuum. J.Buckwalter, M.Lotz and Stolz J-F Eds. IOS Press Amsterdam. 2007;267–79.

108 Dayer E, Dayer-M, Roux-Lombard P. Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nature Clinical Practice Rheumatology. 2007;3:512–20.

109 Specter TD, Hart DJ, Nandra D, Doyle DV, Mackillip N, Gallimore JR, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 1997;40:723–7.

110 Punzi L, Ramonda R, Oliviero F, Sfriso P, Mussap M, Plebani P, et al. Value of C-reactive protein determination in erosive osteoarthritis Ann Rheum Dis. 2005;64:965–7.

111 Vignon E, Baibaba JC, Mathieu P, Louisset P, Richard M. Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids. Osteoarthritis Cartilage. 1993;1:115–20.

112 Ritthaler C, Andre B, Kaye O, Kaiser MJ, Bonnet V, Jaspar JM, et al. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthropathies whether erosive or not. Rheumatology. (Oxford) 2000;39:1357–65.

113 Garnero P, Mazières B, Gueguen A, Abbal M, Berdah L, Lequesne M, et al. Cross-sectional association of 10 molecular markers of bone cartilage, and synovium with disease activity and radiologic joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol. 2005;32;697–703.

114 Bobacz K, Maier R, Faika C, Ekhart H, Wołoszewczuk W, Geyer Y, et al. Is pro-matrix metalloproteinase-3 a marker for posttraumatic cartilage degradation? Osteoarthritis Cartilage. 2003;11:665–72.

115 Boldberg RL, Huff JP, Lenz ME, Glickman P, Katz R, Thoman EJ. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34:799–807.

116 Sharif M, George E, Shepstone L, Knudson W, Thonar EJ, Cushnaghan J, et al. Serum hyaluronate level as a predictor of disease progression in osteoarthritis of the knee. J Rheumatol. 1995;38:760–7.

117 Sharif M, Saxne T, Shepstone L, et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol. 1995;34:306–10.

118 Conrozier T, Saxne T, Fan CS, et al. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis. 1998;57:527–32.

119 Dragomir AD, Kraus VB, Renner JB, Luta G, Clark A, Vilm I, Hochberg MC, Helmick CG, Jordan JM. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage. 2002;10:707–13.

120 Bleasel JF, Poole AR, Heinegard D, Saxne T, Holderbaum D, Ionescu M, et al. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum. 1999;42:39–45.

121 Williams FM, Andrew T, Saxne T, Heinegard D, Spector TD, MacGregor AJ. The heritable determinants of cartilage oligomeric matrix protein. Arthritis Rheum. 2006;54:2147–51.

122 Mazières B, Garnero P, Guéguen A, Abbal M, Berdah L, Lequesne M, et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis. 2006;65:354–9.

123 Deberg M, Labasse A, Christgau S, Cloos P, Bang Henrikson D, et al. New serum biochemical markers (Coll 2-1 and Coll 2-1NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage. 2005;13:258–65.

124 Ramonda R, Deberg M, Campana C, Frigato M, Bosselot A, Henrotin Y, Punzi L. Collagen and non-collagenous matrix proteins in patients with erosive and non-erosive osteoarthritis of the hand. Osteoarthritis Cartilage. 2008;16(suppl 4):S56.

125 Silvestri T, Pulsatelli L, Dolzani P, Punzi L, Meliconi R. Analysis of cartilage markers in erosive and non-erosive osteoarthritis of the hand. Osteoarthritis Cartilage. 2004;12:45–53.

126 Altman R, Ashl E, Bloch D, Bole G, Boreinstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039–49.

127 Punzi L, Ramonda R, Sfriso P. Erosive osteoarthritis. Best Pract Res Clin Rheumatol. 2004;5:739–58.

128 Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al; ESCISIT EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis. 2009;68:8–17.

129 Tan AL, Grainger AJ, Tanner SF, et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis. 2005;64:2147–51.

130 Punzi L, Ramonda R, Phenotyping osteoarthritis of the knee joint. Br J Rheumatol. 1995;34:306–10.

131 Vignon E, Balblanc JC, Mathieu P, Louisset P, Richard M. Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids. Osteoarthritis Cartilage. 1993;1:115–20.

132 Ritthaler C, Andre B, Kaye O, Kaiser MJ, Bonnet V, Jaspar JM, et al. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthropathies whether erosive or not. Rheumatology. (Oxford) 2000;39:1357–65.

133 Garnero P, Mazières B, Gueguen A, Abbal M, Berdah L, Lequesne M, et al. Cross-sectional association of 10 molecular markers of bone cartilage, and synovium with disease activity and radiologic joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol. 2005;32;697–703.

134 Hawker GA, Stewart L, French MR, Cibere J, Jordan JM, March L, et al. Understanding the pain experience in hip and knee osteoarthritis. Arthritis Care Res. 2003;51:326–31.

135 Ghedini M, Farina L, Valvason C, Todesco S. Laboratory investigations in osteoarthritis. Semin Arthritis Rheum. 2005;34:2S:58–61.

136 Maillefert JF, Kloppenburg M, Fernandes L, Punzi L, Günther KP, Martin Mola E, et al. Multi-language translation and cross-cultural adaptation of the OARSI/OMERACT measure of intermittent and constant osteoarthritis pain (ICOAP). Osteoarthritis Cartilage. 2009;17:1293–6.

137 Doninick KL, Ahern FM, Gold CH, Heller DA. Health-related quality of life and health service use among older adults with osteoarthritis. Arthritis Rheum. 2004;51:326–31.

138 Wells KB, Steward A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA. 1989;262:914–9.

139 Creamer P, Leefthbridge-Ceuku M, Hochberg MC. Factors associated with functional impairment in symptomatic knee osteoarthritis. Rheumatology. (Oxford) 2000;39:957–60.

140 Lin EH, Katon W, Von Korff M, Tang L, Williams JW Jr, Kroenke K, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis. JAMA. 2003;290:2428–34.
New horizons in osteoarthritis

Jordan KM, Arden NK, Doherty M, Bamhwarth B, Bijlsma JWJ, Dieppe P, et al. EULAR recommendations 2003: an evidence based medicine approach to knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–55.

Zhang W, Doherty M, Arden N, Bamhwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis - report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:5:669–81.

Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden N, Bijlsma J, et al. EULAR evidence based recommendations for the management of hand osteoarthritis - report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT) Ann Rheum Dis. 2007;66:377–88.

Zhang W, Moskowizt RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15:981–1000.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137–62.

Brittberg M, Lindahl A, Nilsson A, Ohdsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994;331:889–95.

Almarza AJ, Athanasiou KA. Design characteristics for the tissue engineering of cartilaginous tissues. Ann Biomed Eng. 2004;32:2–17.

Hui JH, Chen F, Thambyah A, Lee EH. Treatment of chondral lesions in advanced osteoarthritis discieans: a comparative study of the efficacy of chondrocytes, mesenchymal stem cells, periosteal graft, and mosaicplasty (osteochondral autograft) in animal models. J Pediatr Orthop. 2004;24:427–33.

Nixon AJ, Haupt JL, Frisbie LD, Morisset SS, McIlwraith CW, Robbins PD, et al. Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-1/interleukin-1 receptor antagonist therapy. Gene Ther. 2005;12:177–86.

Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther. 2004;11:379–89.

Hannon GJ. RNA interference. Nature. 2002;418:244–51.

Tu G, Xu W, Huang H, Li S. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem. 2008;15:1388–95.

Ho LJ, Lin LC, Hung LF, Wang SJ, Lee CH, Chang DM, et al. Rettinoic acid blocks pro-inflammatory cytokine-induced matrix metalloproteinase production by down-regulating JNK-AP-1 signaling in human chondrocytes. Biochem Pharmacol. 2005;70:200–8.

Finckh A, Gabay C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol. 2008;20:269–75.

Berdenbaum F. New horizons and perspective in the treatment of osteoarthritis. Arthritis Res Ther 2008;10(Suppl)1:S1–7.

Bursavich MG, Gilbert AM, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, et al. Synthesis and evaluation of arylthioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg Medicin Chem Lett 2007;17:1185–8.

Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG 116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12 month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9:R109.

Chevalier X, Migneir B, Bouvenot G. Targeted anti-cytokine therapies for osteoarthritis. Bull Acad Natl Med. 2006;190:1411–20.

Caron JP, Fernandez JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005;32:1317–23.

Chevalier X, Goupille P, Beaulieu AD, Burch FX, Marchale P, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61:344–52.

Yang KG, Rajmakers NJH, van Arkel ERA, Caron JG, Rijk PC, Willems WJ, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage. 2008;16:498–505.

Brzuske D, Petron D. Treating knee osteoarthritis with intra-articular hyaluronans. Curr Med Res Opin. 2008;24:3307–22.

Paniz L. The complexity of the mechanisms of action of hyaluronan in joint diseases. Clin Exp Rheumatol. 2001;19:242–6.

Goldberg, VM. Buckwalter, JA. Hyaluronan in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage. 2005;13:216–24.

Bellamy, N; Campbell, J; Robinson, V; Cree, T; Bourne, R; Wells, G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 CD005321.

Strassu SJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. 2009;37:1636–44.
Figure 1. Chondrocyte changes induced by mechanical stress
Legend to Figure 1. Chondrocytes can respond to direct biomechanical perturbation by increasing expression of inflammatory mediators, including cytokines and proteinases, and stress response factors. Chondrocytes have receptors for responding to mechanical stimulation (mechano-receptors), many of which are also receptors for extracellular matrix (ECM) components, including: integrins, a receptor for fibronectin and type II collagen fragments; discoidin domain receptor-2 (DDR-2), a receptor of native II collagen fibrils; annexin-V, a receptor of collagen II fragments. All these receptors interacts with intracellular signaling molecules to transduce mechanical signals into biochemical responses which lead to a production of number of proinflammatory substances, including cytokines, proteolytic enzymes, NO and PGE2. The most important among these intracellular signal cascades are NF-κB and MAPK pathways. The MAPK family, which include p38, Erk 1 and 2, and JNK, is of critical importance for cell survival, cell differentiation, and chondrogenesis. Other interesting ways stimulated by mechanical forces are the stretch-activated ion channels (SACs), which are believed to respond to membrane tension, interacting with integrins and leading to an elevation of intra-cellular calcium. This may stimulate mitochondria to release AIF and cytochrome c, which in turn activate pro-caspases 9 and 3 to produce caspase 9 and capsase 3, involved in chondrocyte apoptosis. To this process may also contributes calpains, a family of proteolytic enzymes stimulated by the rise in cytoplasmatic calcium from the ERG and mitochondria.
### Table 1. MOST RELEVANT BIOMARKERS IN OSTEOARTHRITIS

| Tissue of origin | Specimen | Markers of Synthesis | Markers of Degradation |
|------------------|----------|----------------------|------------------------|
| **Bone**         | Serum    | PINP, PICP, bone specific ALP, osteocalcin | PYD, DPD, NTX-I, CTX-I, ICTP, BAP, cathepsin K |
|                  | Synovial fluid | ND | EBP |
|                  | Urine    | HP | CTX-I, DPD, PYD, NTX-I |
| **Cartilage**    | Serum    | CS384, CS383, CS784, PICP, PINP, PINP, YKL-40, TIMPs | CPP, ESSD4, KSANP1, Coll 2-1, Coll2-1NO2, COL2-34m, COL2-14N1, CTX-II, 2B4, COMP, MMPs |
|                  | Synovial fluid | CS384, CS383, CS784, PICP, PINP, YKL-40, TIMPs | CPP, ESSD4, KSANP1, Coll2-34m, COL2-14N1, CTX-II, COMP, MMPs |
|                  | Urine    | ND | CTX-II, HELIX-II, TINE |
| **Synovial membrane** | Serum | PICP, PINP, HA, YKL-40, COMP, MMPs, TIMPs, Cytokines | PYD, Glc-Gal-PYD, CTX-I, NTX-I |
|                  | Synovial fluid | PICP, PINP, YKL-40, COMP, MMPs, TIMPs, Cytokines | PYD |
|                  | Urine    | ND | CTX-II, Glc-Gal-PYD, PYD |

PINP: collagen I N-terminal propeptide; PICP: Procollagen I C-terminal propeptide; ALP: alkaline phosphatase; PYD: pyridinoline; DPD: deoxypyridinoline; NTX-I: N-terminal cross-linking telopeptide of type I collagen; ICTP: C-terminal cross-linking telopeptide of type I collagen; COL2-1: C-terminal cross-linking telopeptide of type II collagen; COMP: cartilage-derived growth factor; CS384: chondroitin sulphate epitope 384; CS784: chondroitin sulphate epitope 784; ESSD4: C-terminal cross-linking telopeptide of type II collagen; KSANP1: keratan sulphate epitope 152; 2B4: truncated form of Coll2-1; COL2-1NO2: nitration form of Coll2-1; COL2-34m: type II collagen denaturation product; COL2-14N1: type II collagen denaturation product; CTX-II: C-terminal cross-linking telopeptide of type II collagen; COMP: cartilage-derived growth factor; MMPs: matrix metalloproteinase; HELIX-II: type II collagen helical peptide I; TINE: collagen type II N-peptide; HA: hyaluronic acid; Glc-Gal-PYD: glucosyl-galactosyl-pyridinoline; PINP: type III collagen N-propeptide.